Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.
Bobin A, Kyheng M, Guidez S, Gruchet-Merouze C, Richez V, Duhamel A, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Perrot A, Roussel M, Jaccard A, Petillon MO, Belhadj-Merzoug K, Chretien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Moreau P, Avet-Loiseau H, Hulin C, Facon T; Intergroupe Francophone du Myelome Multiple (IFM); Leleu X. Bobin A, et al. Leukemia. 2022 Mar;36(3):881-884. doi: 10.1038/s41375-021-01415-x. Epub 2021 Oct 14. Leukemia. 2022. PMID: 34650225 No abstract available.
Current treatment strategies for multiple myeloma.
Grosbois B, Decaux O, Azais I, Facon T, Avet-Loiseau H. Grosbois B, et al. Eur J Intern Med. 2002 Mar;13(2):85-95. doi: 10.1016/s0953-6205(01)00205-9. Eur J Intern Med. 2002. PMID: 11893464
Stem-cell transplantation in multiple myeloma.
Harousseau JL, Moreau P, Attal M, Facon T, Avet-Loiseau H. Harousseau JL, et al. Best Pract Res Clin Haematol. 2005;18(4):603-18. doi: 10.1016/j.beha.2005.01.005. Best Pract Res Clin Haematol. 2005. PMID: 16026740 Review.
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Roland V, Mahé B, Juge-Morineau N, Dubruille V, Guillaume T, Vigouroux S, Moreau P, Milpied N, Garand R, Avet-Loiseau H, Harousseau JL. Chevallier P, et al. Leuk Res. 2005 Sep;29(9):1003-7. doi: 10.1016/j.leukres.2005.02.005. Epub 2005 Apr 8. Leuk Res. 2005. PMID: 16038726
353 results